Screener
Xeris Biopharma Holdings, Inc. XERS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
FAQ
- What is Xeris Biopharma Holdings, Inc.'s total equity?
- Xeris Biopharma Holdings, Inc. (XERS) reported total equity of -$9.73M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s total equity changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s total equity increased by 49.6% year-over-year, from -$19.3M to -$9.73M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s total equity?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s total equity has grown at a -16.5% compound annual growth rate (CAGR), from $33.76M to $13.69M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Xeris Biopharma Holdings, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude